SEATTLE – Etubics Corporation announces the election of Gilbert S. Omenn, MD, PhD, to its Board of Directors.
“Dr. Omenn is a welcome addition to Etubics’ Board,” said Dr. Frank Jones, chief executive officer, chairman of the board and founder of Etubics. “His vast scientific and clinical expertise and heartfelt interest in Etubics technology will help to guide the Company to the next level as we enter our Phase IIb clinical trial with our lead product ETBX-011, an immunotherapeutic for metastatic colorectal cancer.”
Dr. Omenn has been Professor of Internal Medicine, Human Genetics, and Public Health at the University of Michigan since 1997 and Director of the Center for Computational Medicine and Bioinformatics since 2005. He served as U of M Executive Vice President for Medical Affairs and as Chief Executive Officer of the University of Michigan Health System from 1997 to 2002. Previously he was Professor of Medicine, Professor of Environmental Health, and Dean of the School of Public Health and Community Medicine at the University of Washington, and a Member and Trustee of the Fred Hutchinson Cancer Research Center. Dr. Omenn is an affiliate faculty member of the Institute for Systems Biology in Seattle. He is board-certified in Internal Medicine and Medical Genetics. His research focuses on cancer proteomics, bioinformatics, eco-genetics, and risk assessment. Dr. Omenn chairs the international Human Proteome Project.
Dr. Omenn has served as a Director of Amgen Inc. since 1987. He serves on the boards of The Hastings Center for Bioethics, Population Services International, the Center for Public Integrity, CRDFGlobal, CNA, and the Salzburg Global Seminar. He was president and chairman of the board of the American Association for the Advancement of Science in 2005-2007. Earlier he chaired the Presidential/Congressional Commission on Risk Assessment and Risk Management from 1994 to 1997, was Associate Director of the Office of Science and Technology Policy and Associate Director of the Office of Management and Budget in the Executive Office of the President of the United States from 1977 to 1981, was a White House Fellow at the Atomic Energy Commission, and was an investigator of the Howard Hughes Medical Institute. He served on the boards of the Seattle Symphony Orchestra, the Seattle Youth Symphony Orchestra, and the Seattle Chamber Music Festival, and the Washtenaw County United Way. Dr. Omenn has received several honors and has published 500 scientific papers and edited 18 books.
Dr. Jones, Dr, John Abeles, Dr. Richard Gayle, Dr. Cohava Gelber, and Philip O’Reilly will continue on the Board of Directors for Etubics.
Etubics Corporation, based in Seattle, Wash., is a next generation clinical stage bio-pharmaceutical company, which has developed a proprietary platform technology consisting of a next generation Adenovirus Vector Vaccine Platform and a manufacturing E.C7 human cell line, collectively the Etubics Platform. Clinical work to date shows that the Etubics Platform overcomes problems associated with existing adenovirus vectors. The Company’s Platform can be used to efficiently and rapidly develop immunotherapeutic drugs and preventive vaccines for a wide range of infectious diseases and cancers .
Statements herein relating to future financial, business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Etubics is a private company. Etubics cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including the failure by Etubics to secure and maintain relationships with collaborators; risks relating to the early state of Etubics’s product candidates under development; uncertainties relating to clinical trials and regulatory requirements and actions; risks relating to the commercialization, if any, of Etubics proposed product candidates; competitive risks to marketed products; dependence on the efforts of third parties; dependence on intellectual property; and risks that it may lack the financial resources and access to capital to fund its operations. Further information on the factors and risks that could affect Etubics’s offices, business, financial conditions and results of operations, are contained in Etubics’s documents on file at the Company. These forward-looking statements speak only as of the date of this press release and Etubics assumes no duty to update forward-looking statements.
Investor/Media contact: Ms. Ines Tucakovic Clark Phone: (206) 838-5110 Ext. 110 firstname.lastname@example.org